| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide
|
Scotté, F.
|
|
|
29 |
8 |
p. 1718-1726
|
article
|
| 2 |
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
|
Corrie, P.G.
|
|
|
29 |
8 |
p. 1843-1852
|
article
|
| 3 |
Anti-EGFR therapy in oesophagogastric cancer: precise but not enough
|
Salati, M.
|
|
|
29 |
8 |
p. 1884-1885
|
article
|
| 4 |
Artificial intelligence for melanoma diagnosis: how can we deliver on the promise?
|
Mar, V.J.
|
|
|
29 |
8 |
p. 1625-1628
|
article
|
| 5 |
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer
|
Zhang, J.
|
|
|
29 |
8 |
p. 1741-1747
|
article
|
| 6 |
Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease
|
Kamoun, A.
|
|
|
29 |
8 |
p. 1814-1821
|
article
|
| 7 |
Different menopausal hormone regimens and risk of breast cancer
|
Brusselaers, N.
|
|
|
29 |
8 |
p. 1771-1776
|
article
|
| 8 |
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
|
Ochoa de Olza, M.
|
|
|
29 |
8 |
p. 1727-1740
|
article
|
| 9 |
Editorial Board
|
|
|
|
29 |
8 |
p. ii-iii
|
article
|
| 10 |
ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients
|
Hutchings, M.
|
|
|
29 |
8 |
p. 1687-1700
|
article
|
| 11 |
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
|
Honecker, F.
|
|
|
29 |
8 |
p. 1658-1686
|
article
|
| 12 |
HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
|
Fotopoulou, C.
|
|
|
29 |
8 |
p. 1610-1613
|
article
|
| 13 |
Identifying patients who may benefit from oxaliplatin-containing perioperative chemo(radio)therapy for rectal cancer
|
Papamichael, D.
|
|
|
29 |
8 |
p. 1616-1618
|
article
|
| 14 |
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial
|
Hofheinz, R.-D.
|
|
|
29 |
8 |
p. 1793-1799
|
article
|
| 15 |
Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists
|
Haenssle, H.A.
|
|
|
29 |
8 |
p. 1836-1842
|
article
|
| 16 |
Mediastinal lymph node clearance and anti-PD-1 induction in resected NSCLC
|
Manapov, F.
|
|
|
29 |
8 |
p. 1879
|
article
|
| 17 |
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial
|
Arnedos, M.
|
|
|
29 |
8 |
p. 1755-1762
|
article
|
| 18 |
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
|
Yardley, D.A.
|
|
|
29 |
8 |
p. 1763-1770
|
article
|
| 19 |
Now the dust has settled over immune checkpoint blockade in metastatic prostate cancer
|
Mehra, N.
|
|
|
29 |
8 |
p. 1620-1622
|
article
|
| 20 |
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
|
Malorni, L.
|
|
|
29 |
8 |
p. 1748-1754
|
article
|
| 21 |
PARPi related toxicities: do we need more appropriate instruments to evaluate it?
|
Lorusso, D.
|
|
|
29 |
8 |
p. 1613-1616
|
article
|
| 22 |
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
|
Tetzlaff, M.T.
|
|
|
29 |
8 |
p. 1861-1868
|
article
|
| 23 |
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
|
Cottrell, T.R.
|
|
|
29 |
8 |
p. 1853-1860
|
article
|
| 24 |
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
|
Hansen, A.R.
|
|
|
29 |
8 |
p. 1807-1813
|
article
|
| 25 |
Pleural mesothelioma: is the surgeon still there?
|
Opitz, I.
|
|
|
29 |
8 |
p. 1710-1717
|
article
|
| 26 |
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
|
Bonomi, P.D.
|
|
|
29 |
8 |
p. 1701-1709
|
article
|
| 27 |
Prognostic gene expression signatures in sarcoma: finding clarity in complexity
|
Charville, G.W.
|
|
|
29 |
8 |
p. 1632-1633
|
article
|
| 28 |
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
|
Maurer, M.J.
|
|
|
29 |
8 |
p. 1822-1827
|
article
|
| 29 |
Reply to the letter to the editor ‘Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer’ by Yang et al.
|
Conteduca, Vincenza
|
|
|
29 |
8 |
p. 1879-1880
|
article
|
| 30 |
Reply to the letter to the editor ‘Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses’ by Kaiser et al.
|
Rugo, H.S.
|
|
|
29 |
8 |
p. 1878
|
article
|
| 31 |
Reply to the letter to the editor: ‘The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?’ By P. Trendsz et al.
|
Sobrero, A.
|
|
|
29 |
8 |
p. 1883-1884
|
article
|
| 32 |
Reporting of HRQoL results from the PALOMA-2 trial: Relevant data are still missing
|
Kaiser, T.
|
|
|
29 |
8 |
p. 1877
|
article
|
| 33 |
Safety and dose modification for patients receiving niraparib
|
Berek, J.S.
|
|
|
29 |
8 |
p. 1784-1792
|
article
|
| 34 |
Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven’t found what we’re looking for
|
Robson, M.
|
|
|
29 |
8 |
p. 1609-1610
|
article
|
| 35 |
Selective RET kinase inhibition for patients with RET-altered cancers
|
Subbiah, V.
|
|
|
29 |
8 |
p. 1869-1876
|
article
|
| 36 |
Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study
|
Wästerlid, T.
|
|
|
29 |
8 |
p. 1882-1883
|
article
|
| 37 |
Surrogate end points in lymphoma
|
Batlevi, C.L.
|
|
|
29 |
8 |
p. 1622-1623
|
article
|
| 38 |
Table of Contents
|
|
|
|
29 |
8 |
p. iv-vii
|
article
|
| 39 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
|
Morano, F.
|
|
|
29 |
8 |
p. 1800-1806
|
article
|
| 40 |
The right chance for temozolomide in metastatic colorectal cancer?
|
Sartore-Bianchi, A.
|
|
|
29 |
8 |
p. 1618-1619
|
article
|
| 41 |
The right compound for the right target: tackling RET
|
Seoane, J.
|
|
|
29 |
8 |
p. 1623-1625
|
article
|
| 42 |
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) † † These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO).
|
Cardoso, F.
|
|
|
29 |
8 |
p. 1634-1657
|
article
|
| 43 |
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
|
Ignatiadis, M.
|
|
|
29 |
8 |
p. 1777-1783
|
article
|
| 44 |
Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor
|
Verstovsek, S.
|
|
|
29 |
8 |
p. 1880-1882
|
article
|
| 45 |
Tumor-treating fields: time for demystification
|
Weller, M.
|
|
|
29 |
8 |
p. 1628-1630
|
article
|
| 46 |
Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors
|
Sholl, L.M.
|
|
|
29 |
8 |
p. 1630-1632
|
article
|
| 47 |
Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas
|
Le Guellec, S.
|
|
|
29 |
8 |
p. 1828-1835
|
article
|
Journal description